Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia

NCT06223919 is registered in ClinicalTrials.gov with Universidad Nacional de Colombia as lead sponsor.

NCT NCT06223919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia
Lead sponsor
Universidad Nacional de Colombia
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 16, 2023
Completion date
December 31, 2025
Enrollment
8,686 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

monkeypox